Skinvisible Pharmaceuticals

Skinvisible Pharmaceuticals is a drug delivery technology company leveraging its proprietary Invisicare® polymer platform to create enhanced topical and transdermal formulations. Its pipeline is strategically focused on dermatology, rare skin diseases, and the high-growth obesity/metabolic health market, aiming to provide needle-free alternatives to injections. The company follows a capital-light, partnership-driven business model, licensing its technology to development and commercial partners, as evidenced by its active collaboration with Quoin Pharmaceuticals for Netherton Syndrome.

Invisicare®: a patented polymer-based system for topical and transdermal drug delivery enabling controlled release, enhanced skin adhesion, and improved penetration without patches or encapsulation.

Skinvisible competes in the crowded drug delivery technology space, facing competition from other transdermal patch developers, oral formulation specialists, and large pharmaceutical companies' internal R&D. Its key differentiator is the polymer-based Invisicare system claiming high penetration without complex devices, but it must prove clinical superiority or significant convenience advantages to secure major partnerships.